Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CARES Human ECM-based platform for anti-cancer drug testing - CARES (CAncer dRug tESting)

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 November 2023 to 31 October 2027
Status
Running
EU funding
€276k
Total cost
—
Partners
11 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101130985

What the project is doing

In the project's own words, from its summary on CORDIS.

With 2 million cancer-related deaths and an annual cost of €100 billion, cancer constitutes a major European challenge. Cancertreatments have considerably improved over the last decades, however, the success rate of new anti-cancer drugs in clinical trialsremains frustratingly low, limiting the opportunities for fast and accurate development of innovative targeted cancer therapies. Ourvision is to provide a bold and innovative technology that recapitulates the active part played by the human tumourmicroenvironment, which has crucial roles in regulating tumour initiation, propagation, and progression, through the dynamiccrosstalk between the tumour cells and the extracellular matrix.

CARES combines leading academic and non-academic experts in thefields of matrix biology, biomaterials, microfluidics and cancer research to establish an accurate tool to assess cancer cell responses toa variety of anti-cancer drugs. As a proof-of-concept, we will use breast cancer cells as a model system, with the perspective ofextending the system to other cancers. Our final goal is to deliver a novel and user-friendly platform that, by resembling the humantumour microenvironment in early and advanced cancer stages, can predict, with unprecedented accuracy, the response of tumourcells to anti-cancer therapies in vivo.

This will facilitate development and testing of new drugs and narrow the gap betweentranslational cancer research and targeted cancer treatment, with a significant impact on society and the economy. The ambitiousscientific goal will provide the background for intense trans-sectoral and interdisciplinary training of young scientists, who will beprovided with an excellent translational research portfolio, allowing them to succeed both in academia and industry.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator
Universidad Del Noroeste De La Provincia De Buenos AiresJuninARAssociatedpartner
Universitaet Fuer Bodenkultur WienWienAustriaParticipant
Serend-Ip GmbHMuensterGermanyParticipant
Universitaet MuensterMuensterGermanyParticipant
Panepistimio PatronRio PatrasGreeceParticipant
Oulun YliopistoOuluFinlandParticipant
Probiont OyHelsinkiFinlandParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceAssociatedpartner
Universita Degli Studi Dell'insubriaVareseItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI